Risk Factors for Predicting Severe Neutropenia Induced by Amrubicin in Patients with Advanced Lung Cancer-Reference-Cited by-同舟云学术

Risk Factors for Predicting Severe Neutropenia Induced by Amrubicin in Patients with Advanced Lung Cancer

Published:2012 Issue:6 Volume:58 Page:419-425
ISSN:1421-9794
Container-title:Chemotherapy
language:en
Short-container-title:Chemotherapy

Author:

Watanabe Hiroyuki,Ikesue Hiroaki,Oshiro Marina,Nagata Kenichiro,Mishima Kazuto,Takada Atsushi,Suetsugu Kimitaka,Sueyasu Masanori,Egashira Nobuaki,Harada Taishi,Takayama Koichi,Nakanishi Yoichi,Oishi Ryozo

Publisher

S. Karger AG

Subject

Infectious Diseases,Pharmacology (medical),Drug Discovery,Pharmacology,Oncology,General Medicine

Reference29 articles.

1. A New Antitumor Agent Amrubicin Induces Cell Growth Inhibition by Stabilizing Topoisomerase II-DNA Complex

2. Cytotoxicity of Amrubicin, a Novel 9-Aminoanthracycline, and Its Active Metabolite Amrubicinol on Human Tumor Cells

3. Characterization of the enzymes involved in thein vitrometabolism of amrubicin hydrochloride

4. Phase II Trial of Amrubicin for Treatment of Refractory or Relapsed Small-Cell Lung Cancer: Thoracic Oncology Research Group Study 0301

5. Phase II study of amrubicin in previously untreated patients with extensive-disease small cell lung cancer: West Japan Thoracic Oncology Group (WJTOG) study

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Detection of factors related to treatment reduction in docetaxel and ramucirumab for non-small cell lung cancer treatment;Scientific Reports;2023-11-09

2. Risk Factor Analysis for the Occurrence of Severe Adverse Effects in Eribulin Treatment;Anticancer Research;2022-07

3. Risk factors for severe neutropenia in pancreatic cancer patients treated with gemcitabine/nab-paclitaxel combination therapy;PLOS ONE;2021-07-14

4. Patient factors and their impact on neutropenic events: a systematic review and meta-analysis;Supportive Care in Cancer;2019-04-16

5. Pharmacokinetic-Pharmacodynamic Model of Neutropenia in Patients With Myeloma Receiving High-Dose Melphalan for Autologous Stem Cell Transplant;CPT: Pharmacometrics & Systems Pharmacology;2018-10-20